A mobile tool to help patients with urothelial carcinoma assess their quality of life

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather insights from patients diagnosed with urothelial carcinoma to inform the development of a web app designed to enhance their quality of life assessment and monitoring. Participants, who are candidates for systemic treatments or already undergoing treatment, will complete questionnaires to identify useful content and tools for the app. The goal is to empower patients by improving their understanding of urothelial carcinoma and its treatment options, ultimately facilitating better decision-making. The study focuses on patient-directed input to ensure the app meets their needs effectively.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histological diagnosis of urothelial carcinoma;
* ≥ 18 years old,
* candidate for systemic treatment with chemotherapy, immune-checkpoint inhibitors, antibody-drug conjugates, or target therapy (patients can be enrolled also if the treatment has started),
* possession of a mobile device (e.g., smartphone or personal computer) with the physical and psychological ability to use mobile devices,
* understanding and speaking the Italian language,
* ability to sign an informed consent.

Exclusion Criteria:

* not possession of a mobile device,
* unwillingness to give informed consent.

Where it's running

• IRCCS San Raffaele
  Milan, Italy, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• Trop2-targeted NIR-II probe to identify bladder cancer in ex vivo samples

  A phase 2 study tests whether a Trop2-targeted NIR-II fluorescent probe can highlight bladder cancer lesions on ex vivo bladder tissue from patients undergoing radical cystectomy.

  Recruiting Phase 2 Yunnan Cancer Hospital · Kunming, Yunnan · NCT07848854

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Blood test for detecting tumor DNA in bladder and upper tract cancer

  A blood test that looks for tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer is being tested to see if it matches what’s found in tumor tissue and if it can help track recurrence or remission over two years.

  Recruiting AZ Sint-Lucas Gent · Ghent, East Flanders · NCT07756437

• Specimen Collection for Validation of a New urine-based bladder cancer test

  This study collects urine and tumor samples from adults being evaluated or treated for urothelial cancer to validate a next‑generation sequencing platform.

  Recruiting Convergent Genomics, Inc. · Oceanside, California and 22 other locations · NCT07673016

• Non-invasive urine test to screen for urothelial cancer in adults with blood in urine

  A noninvasive urine test is being used to see if it can correctly identify urothelial cancer in adults who have blood in urine and a suspicious imaging finding.

  Recruiting Henan Provincial People's Hospital · Zhengzhou, Henan · NCT07614594

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.